ATE254614T1 - Tetrahydro-benzo(d)azepine und deren verwendung als metabotrope glutamatrezeptor-antagonisten - Google Patents

Tetrahydro-benzo(d)azepine und deren verwendung als metabotrope glutamatrezeptor-antagonisten

Info

Publication number: ATE254614T1
Authority: AT; Austria
Prior art keywords: glutama; azepines; metabotropic; benzo; tetrahydro
Prior art date: 1999-08-06

Application number

AT00116091T

Other languages

English (en)

Inventor

Geo Adam

Alfred Binggeli

Hans-Peter Maerki

Vincent Mutel

Maurice Wilhelm

Wolfgang Wostl

Original Assignee

Hoffmann La Roche

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-08-06

Filing date

2000-07-27

Publication date

2003-12-15

2000-07-27 Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche

2003-12-15 Application granted granted Critical

2003-12-15 Publication of ATE254614T1 publication Critical patent/ATE254614T1/de

Links

150000001538 azepines Chemical class 0.000 title 1
HSUGRBWQSSZJOP-RTWAWAEBSA-N diltiazem Chemical compound C1=CC(OC)=CC=C1[C@H]1[C@@H](OC(C)=O)C(=O)N(CCN(C)C)C2=CC=CC=C2S1 HSUGRBWQSSZJOP-RTWAWAEBSA-N 0.000 title 1
239000002464 receptor antagonist Substances 0.000 title 1
229940044551 receptor antagonist Drugs 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
General Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Chemical Kinetics & Catalysis (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Psychiatry (AREA)
Pain & Pain Management (AREA)
Hospice & Palliative Care (AREA)
Cardiology (AREA)
Addiction (AREA)
Urology & Nephrology (AREA)
Heart & Thoracic Surgery (AREA)
Diabetes (AREA)
Psychology (AREA)
Vascular Medicine (AREA)
Emergency Medicine (AREA)
Endocrinology (AREA)
Hematology (AREA)
Ophthalmology & Optometry (AREA)
Obesity (AREA)
Otolaryngology (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Plural Heterocyclic Compounds (AREA)
Other In-Based Heterocyclic Compounds (AREA)

AT00116091T 1999-08-06 2000-07-27 Tetrahydro-benzo(d)azepine und deren verwendung als metabotrope glutamatrezeptor-antagonisten ATE254614T1 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
EP99115557		1999-08-06

Publications (1)

Publication Number	Publication Date
ATE254614T1 true ATE254614T1 (de)	2003-12-15

Family

ID=8238742

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT00116091T ATE254614T1 (de)	1999-08-06	2000-07-27	Tetrahydro-benzo(d)azepine und deren verwendung als metabotrope glutamatrezeptor-antagonisten

Country Status (27)

Country	Link
US (1)	US6218385B1 (de)
JP (1)	JP3260350B2 (de)
KR (1)	KR100390116B1 (de)
CN (1)	CN1146455C (de)
AR (1)	AR025035A1 (de)
AT (1)	ATE254614T1 (de)
AU (1)	AU774485B2 (de)
BR (1)	BR0003375A (de)
CA (1)	CA2314798A1 (de)
CO (1)	CO5180625A1 (de)
DE (1)	DE60006618T2 (de)
ES (1)	ES2209728T3 (de)
HR (1)	HRP20000520A2 (de)
HU (1)	HUP0003112A3 (de)
ID (1)	ID26743A (de)
IL (1)	IL137688A0 (de)
MA (1)	MA26748A1 (de)
NO (1)	NO20003966L (de)
NZ (1)	NZ506096A (de)
PE (1)	PE20010467A1 (de)
PL (1)	PL341890A1 (de)
RU (1)	RU2240317C2 (de)
SG (1)	SG93251A1 (de)
TR (1)	TR200002298A2 (de)
UY (1)	UY26276A1 (de)
YU (1)	YU49700A (de)
ZA (1)	ZA200003927B (de)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PT1345609E (pt) *	2000-12-22	2005-08-31	Hoffmann La Roche	Derivados de tetra-hidro-(benzo ou tieno)-azepina-pirazina como antagonistas de mglur 1
US6953787B2 (en)	2002-04-12	2005-10-11	Arena Pharmaceuticals, Inc.	5HT2C receptor modulators
EP2133340B1 (de)	2002-12-20	2013-01-16	Glaxo Group Limited	Neuartige Benzazepin-Derivate
CN1805938B (zh) *	2003-06-17	2010-06-16	艾尼纳制药公司	用于治疗5ht2c受体相关疾病的苯并氮杂卓衍生物
HUE028976T2 (en) *	2003-06-17	2017-02-28	Arena Pharm Inc	8-Chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine hydrochloride
WO2005042491A1 (en) *	2003-10-22	2005-05-12	Arena Pharmaceuticals, Inc.	Benzazepine derivatives and methods of prophylaxis or treatment of 5ht2c receptor associated diseases
WO2005042490A1 (en) *	2003-10-22	2005-05-12	Arena Pharmaceuticals, Inc.	Benzazepine derivatives and methods of prophylaxis or treatment of 5ht2c receptor associated diseases
SI1838677T1 (sl)	2004-12-21	2010-01-29	Arena Pharm Inc	Kristalne oblike (R)-8-kloro-1-metil-2,3,4,5-tetrahidro-1H-3-benzazepin hidroklorida
SG158168A1 (en)	2004-12-23	2010-01-29	Arena Pharm Inc	5ht2c receptor modulator compositions and methods of use
EP2258358A3 (de)	2005-08-26	2011-09-07	Braincells, Inc.	Neurogenese mit Acetylcholinesterasehemmer
EP1928437A2 (de)	2005-08-26	2008-06-11	Braincells, Inc.	Neurogenese mittels muscarinrezeptormodulation
EP1940389A2 (de)	2005-10-21	2008-07-09	Braincells, Inc.	Modulation von neurogenese durch pde-hemmung
US20070112017A1 (en)	2005-10-31	2007-05-17	Braincells, Inc.	Gaba receptor mediated modulation of neurogenesis
US20100216734A1 (en)	2006-03-08	2010-08-26	Braincells, Inc.	Modulation of neurogenesis by nootropic agents
EP2471779A1 (de)	2006-04-03	2012-07-04	Arena Pharmaceuticals, Inc.	Verfahren zur Trennung einer Mischung von (R)- und (S)-8-Chlor-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepin
WO2007134077A2 (en)	2006-05-09	2007-11-22	Braincells, Inc.	5 ht receptor mediated neurogenesis
AU2007249399A1 (en)	2006-05-09	2007-11-22	Braincells, Inc.	Neurogenesis by modulating angiotensin
EP1873527A1 (de) *	2006-06-30	2008-01-02	Schwarz Pharma Ag	Verfahren zur Identifizierung von CRMP-Modulatoren
EP2068872A1 (de)	2006-09-08	2009-06-17	Braincells, Inc.	Kombinationen mit einem 4-acylaminopyridin-derivat
US20100184806A1 (en)	2006-09-19	2010-07-22	Braincells, Inc.	Modulation of neurogenesis by ppar agents
ES2610508T3 (es)	2006-11-22	2017-04-27	Clinical Research Associates, Llc	Métodos para tratar el síndrome de Down, el síndrome del cromosoma X frágil y el autismo
US8299241B2 (en) *	2006-12-05	2012-10-30	Arena Pharmaceuticals, Inc.	Processes for preparing (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine and intermediates thereof
TW200845978A (en) *	2007-03-07	2008-12-01	Janssen Pharmaceutica Nv	3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives
CN102015591B (zh)	2008-03-04	2014-01-29	艾尼纳制药公司	制备与5-ht2c激动剂(r)-8-氯-1-甲基-2，3，4，5-四氢-1h-3-苯并氮杂卓相关的中间体的方法
WO2010099217A1 (en)	2009-02-25	2010-09-02	Braincells, Inc.	Modulation of neurogenesis using d-cycloserine combinations
US8952197B2 (en)	2009-06-18	2015-02-10	Arena Pharmaceuticals, Inc.	Processes for the preparation of 5-HT2C receptor agonists
US20130058915A1 (en)	2010-03-02	2013-03-07	Children's Medica Center Corporation	Methods and compositions for treatment of angelman syndrome and autism spectrum disorders
WO2011150380A1 (en)	2010-05-28	2011-12-01	Xenoport, Inc.	Methods of treatment of fragile x syndrome, down's syndrome, autism and related disorders
KR20130112848A (ko)	2010-06-02	2013-10-14	아레나 파마슈티칼스, 인크.	5-ｈｔ2ｃ 수용체 아고니스트의 제조 방법
US20120016021A1 (en)	2010-07-15	2012-01-19	Xenoport, Inc.	Methods of treating fragile x syndrome, down's syndrome, autism and related disorders
JP2013536859A (ja)	2010-09-01	2013-09-26	アリーナファーマシューティカルズ，インコーポレイテッド	５−ｈｔ２ｃアゴニストの非吸湿性塩
KR20140091458A (ko)	2010-09-01	2014-07-21	아레나 파마슈티칼스, 인크.	신장 손상을 갖는 개체에 대한 로카세린의 투여
EP3485878A1 (de)	2010-09-01	2019-05-22	Arena Pharmaceuticals, Inc.	Darreichungsformen von 5-ht2c-agonisten, die nützlich für gewichtskontrolle sind
KR20130138770A (ko)	2010-09-01	2013-12-19	아레나 파마슈티칼스, 인크.	광학적으로 활성 산을 갖는 로르카세린의 염
WO2014058441A1 (en)	2012-10-09	2014-04-17	Arena Pharmaceuticals, Inc.	Method of weight management

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4206210A (en) *	1977-01-19	1980-06-03	Smithkline Corporation	Alkylthio-7,8-dihdroxy-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepines having dopaminergic activity
CZ400992A3 (en) *	1990-11-06	1993-12-15	Pfizer	Quinazoline derivatives for enhancing anti-tumor activity
US5241065A (en) *	1992-02-25	1993-08-31	Schering Corporation	2,3,4,5-tetrahydro-1h-3-benzazepines having anti-psychotic activity
AU678503B2 (en) *	1993-09-24	1997-05-29	Takeda Chemical Industries Ltd.	Condensed heterocyclic compounds and their use as squalene synthetase inhibitors

2000
- 2000-07-27 DE DE60006618T patent/DE60006618T2/de not_active Expired - Fee Related
- 2000-07-27 AT AT00116091T patent/ATE254614T1/de not_active IP Right Cessation
- 2000-07-27 ES ES00116091T patent/ES2209728T3/es not_active Expired - Lifetime
- 2000-08-01 US US09/630,702 patent/US6218385B1/en not_active Expired - Fee Related
- 2000-08-01 NZ NZ506096A patent/NZ506096A/xx unknown
- 2000-08-01 MA MA26033A patent/MA26748A1/fr unknown
- 2000-08-01 CA CA002314798A patent/CA2314798A1/en not_active Abandoned
- 2000-08-02 SG SG200004344A patent/SG93251A1/en unknown
- 2000-08-02 ID IDP20000655A patent/ID26743A/id unknown
- 2000-08-02 ZA ZA200003927A patent/ZA200003927B/xx unknown
- 2000-08-02 AU AU48979/00A patent/AU774485B2/en not_active Ceased
- 2000-08-02 PE PE2000000768A patent/PE20010467A1/es not_active Application Discontinuation
- 2000-08-02 HR HR20000520A patent/HRP20000520A2/hr not_active Application Discontinuation
- 2000-08-03 CO CO00058410A patent/CO5180625A1/es not_active Application Discontinuation
- 2000-08-03 IL IL13768800A patent/IL137688A0/xx unknown
- 2000-08-04 JP JP2000236848A patent/JP3260350B2/ja not_active Expired - Fee Related
- 2000-08-04 HU HU0003112A patent/HUP0003112A3/hu unknown
- 2000-08-04 KR KR10-2000-0045324A patent/KR100390116B1/ko not_active Expired - Fee Related
- 2000-08-04 TR TR2000/02298A patent/TR200002298A2/xx unknown
- 2000-08-04 NO NO20003966A patent/NO20003966L/no not_active Application Discontinuation
- 2000-08-04 UY UY26276A patent/UY26276A1/es not_active Application Discontinuation
- 2000-08-04 CN CNB001225235A patent/CN1146455C/zh not_active Expired - Fee Related
- 2000-08-04 RU RU2000120522/04A patent/RU2240317C2/ru not_active IP Right Cessation
- 2000-08-04 AR ARP000104022A patent/AR025035A1/es not_active Application Discontinuation
- 2000-08-07 BR BR0003375-8A patent/BR0003375A/pt not_active Application Discontinuation
- 2000-08-07 PL PL00341890A patent/PL341890A1/xx unknown
- 2000-08-07 YU YU49700A patent/YU49700A/sh unknown

Also Published As

Publication number	Publication date
ES2209728T3 (es)	2004-07-01
TR200002298A3 (tr)	2001-03-21
SG93251A1 (en)	2002-12-17
JP2001089472A (ja)	2001-04-03
CN1283623A (zh)	2001-02-14
NZ506096A (en)	2002-08-28
PL341890A1 (en)	2001-02-12
BR0003375A (pt)	2001-03-13
MA26748A1 (fr)	2004-12-20
ID26743A (id)	2001-02-08
DE60006618D1 (de)	2003-12-24
PE20010467A1 (es)	2001-04-17
HU0003112D0 (en)	2000-10-28
NO20003966D0 (no)	2000-08-04
HUP0003112A2 (hu)	2002-11-28
KR100390116B1 (ko)	2003-07-04
TR200002298A2 (tr)	2001-03-21
AR025035A1 (es)	2002-11-06
DE60006618T2 (de)	2004-09-23
ZA200003927B (en)	2001-02-06
AU774485B2 (en)	2004-07-01
HUP0003112A3 (en)	2003-07-28
KR20010082510A (ko)	2001-08-30
JP3260350B2 (ja)	2002-02-25
HRP20000520A2 (en)	2001-06-30
CO5180625A1 (es)	2002-07-30
NO20003966L (no)	2001-02-07
AU4897900A (en)	2001-02-08
UY26276A1 (es)	2000-10-31
US6218385B1 (en)	2001-04-17
CA2314798A1 (en)	2001-02-06
YU49700A (sh)	2003-04-30
CN1146455C (zh)	2004-04-21
RU2240317C2 (ru)	2004-11-20
IL137688A0 (en)	2001-10-31

Legal Events

Date

Code

Title

Description

2004-07-15

UEP

Publication of translation of european patent specification

Ref document number: 1074549

Country of ref document: EP

2010-04-15

REN

Ceased due to non-payment of the annual fee

Publication	Publication Date	Title
ATE254614T1 (de)	2003-12-15	Tetrahydro-benzo(d)azepine und deren verwendung als metabotrope glutamatrezeptor-antagonisten
ATE261945T1 (de)	2004-04-15	Benzodiazepinderivate und deren verwendung als metabotrope glutamatrezeptor antagonisten
ATE250039T1 (de)	2003-10-15	Benzodiazepinderivate und deren verwendung als metabotrope glutamatrezeptor antagonisten
DE60015296D1 (de)	2004-12-02	Indolderivate und ihre verwendung als mcp-1 rezeptor antagonisten
DE69925730D1 (de)	2005-07-14	4-benzyl-piperidin-alkylsulfoxid-heterozyklen und ihre verwendung als subtyp-selektive nmda rezeptor antagonisten
ATE277905T1 (de)	2004-10-15	4-phenylpyridinderivate und deren verwendung als nk-1 rezeptorantagonisten
DE60114413D1 (de)	2005-12-01	Substituierte 1-aminoalkyl-lactame und deren verwendung als muscarinrezeptor-antagonisten
DE60112322D1 (de)	2005-09-01	Aminothiazole und deren verwendung als adenosinrezeptorantagonisten
EP1105389A4 (de)	2001-10-17	Integrinreceptorantagonisten
DE60106607D1 (de)	2004-11-25	Substituierte 1-aminoalkyl-lactame und ihre verwendung als muscarinrezeptor antagonisten
ATE280158T1 (de)	2004-11-15	3-phenylpyridinderivative und deren verwendung als nk-1 rezeptorantagonisten
HUP0301665A3 (en)	2008-12-29	Novel benzazepines and related heterocyclic derivatives which are useful as orexin receptor antagonists
DK1147115T5 (da)	2008-12-08	Tricycliske benzodiazepiner som vasopressinreceptorantagonister
EP1007051A4 (de)	2001-08-29	Integrin rezeptor antagonisten
EP1194151A4 (de)	2003-01-15	Antagonisten der integrin rezeptoren
EP1229910A4 (de)	2003-10-01	Integrinrezeptorantagonisten
AU9259801A (en)	2002-03-26	Alpha v integrin receptor antagonists
AU2001290772A1 (en)	2002-03-26	Alpha v integrin receptor antagonists
EP1027337A4 (de)	2002-04-03	Integrin-rezeptor-antagonisten
EP1248607A4 (de)	2004-10-06	Urotensin-ii rezeptorantagonisten
IL148043A0 (en)	2002-09-12	Novel integrin receptor antagonists
ATE353881T1 (de)	2007-03-15	1,4-diazepan-2,5-dion-derivate und deren verwendung als nk-1 rezeptorantagonisten
IL146146A0 (en)	2002-07-25	Integrin receptor antagonists
AU5572500A (en)	2001-01-22	Vegf receptor antagonists
SI1187592T1 (sl)	2007-12-31	Antagonisti alfa V integrinskega receptorja